Return of Genetic Results in the Familial Dilated Cardiomyopathy Research Project

Overview

Journal J Genet Couns

Publisher Wiley

Specialty Genetics

Date 2012 Aug 14

PMID 22886719

Citations 11

Authors

Jill D Siegfried

Ana Morales

Jessica D Kushner

Emily Burkett

Jason Cowan

Ana Clara Mauro

Gordon S Huggins

Duanxiang Li

Nadine Norton

Ray E Hershberger

Affiliations

Soon will be listed here.

Abstract

The goal of the Familial Dilated Cardiomyopathy (FDC) Research Project, initiated in 1993, has been to identify and characterize FDC genetic cause. All participating individuals have been consented for the return of genetic results, an important but challenging undertaking. Since the inception of the Project we have enrolled 606 probands, and 269 of these had 1670 family members also enrolled. Each subject was evaluated for idiopathic dilated cardiomyopathy (IDC) and pedigrees were categorized as familial or sporadic. The coding regions of 14 genes were resequenced in 311 to 324 probands in five studies. Ninety-two probands were found to carry nonsynonymous rare variants absent in controls, and with Clinical Laboratory Improvement Amendment of 1988 (CLIA) compliant protocols, relevant genetic results were returned to these probands and their consented relatives by study genetic counselors and physicians in 353 letters. In 10 of the 51 families that received results >1 year ago, at least 23 individuals underwent CLIA confirmation testing for their family's rare variant. Return of genetic results has been successfully undertaken in the FDC Research Project. This report describes the methods utilized in the process of returning research results. We use this information as a springboard for providing guidance to other genetic research groups and proposing future directions in this arena.

Citing Articles

Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.

Hutchcraft M, Zhang S, Lin N, Pickarski J, Belcher E, Wei S JCO Precis Oncol. 2024; 8:e2300266.

PMID: 38295319 PMC: 10843325. DOI: 10.1200/PO.23.00266.

Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer.

Bradbury A, Patrick-Miller L, Egleston B, Maxwell K, DiGiovanni L, Brower J JCO Precis Oncol. 2020; 2.

PMID: 32095738 PMC: 7039346. DOI: 10.1200/po.17.00250.

Titin mutations and muscle disease.

Kellermayer D, Smith 3rd J, Granzier H Pflugers Arch. 2019; 471(5):673-682.

PMID: 30919088 PMC: 6481931. DOI: 10.1007/s00424-019-02272-5.

Genetics of Dilated Cardiomyopathy: Clinical Implications.

Paldino A, de Angelis G, Merlo M, Gigli M, Dal Ferro M, Severini G Curr Cardiol Rep. 2018; 20(10):83.

PMID: 30105555 DOI: 10.1007/s11886-018-1030-7.

Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association.

Musunuru K, Arora P, Cooke J, Ferguson J, Hershberger R, Hickey K Circ Genom Precis Med. 2018; 11(6):e000046.

PMID: 29844141 PMC: 6708587. DOI: 10.1161/HCG.0000000000000046.

References

Hershberger R, Parks S, Kushner J, Li D, Ludwigsen S, Jakobs P . Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy. Clin Transl Sci. 2009; 1(1):21-6. PMC: 2633921. DOI: 10.1111/j.1752-8062.2008.00017.x. View

Morales A, Cowan J, Dagua J, Hershberger R . Family history: an essential tool for cardiovascular genetic medicine. Congest Heart Fail. 2008; 14(1):37-45. DOI: 10.1111/j.1751-7133.2008.08201.x. View

Ledbetter D, Andrew Faucett W . Issues in genetic testing for ultra-rare diseases: background and introduction. Genet Med. 2008; 10(5):309-13. DOI: 10.1097/GIM.0b013e3181729d99. View

Hershberger R, Siegfried J . Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2011; 57(16):1641-9. PMC: 3088091. DOI: 10.1016/j.jacc.2011.01.015. View

Burkett E, Hershberger R . Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005; 45(7):969-81. DOI: 10.1016/j.jacc.2004.11.066. View

Trinidad S, Fullerton S, Ludman E, Jarvik G, Larson E, Burke W . Research ethics. Research practice and participant preferences: the growing gulf. Science. 2011; 331(6015):287-8. PMC: 3044500. DOI: 10.1126/science.1199000. View

Das S, Bale S, Ledbetter D . Molecular genetic testing for ultra rare diseases: models for translation from the research laboratory to the CLIA-certified diagnostic laboratory. Genet Med. 2008; 10(5):332-6. DOI: 10.1097/GIM.0b013e318172838d. View

Rope A, Wang K, Evjenth R, Xing J, Johnston J, Swensen J . Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am J Hum Genet. 2011; 89(1):28-43. PMC: 3135802. DOI: 10.1016/j.ajhg.2011.05.017. View

Norton N, Li D, Rieder M, Siegfried J, Rampersaud E, Zuchner S . Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet. 2011; 88(3):273-82. PMC: 3059419. DOI: 10.1016/j.ajhg.2011.01.016. View

10.

Richards C, Bale S, Bellissimo D, Das S, Grody W, Hegde M . ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med. 2008; 10(4):294-300. DOI: 10.1097/GIM.0b013e31816b5cae. View

11.

Morales A, Pinto J, Siegfried J, Li D, Norton N, Hofmeyer M . Late onset sporadic dilated cardiomyopathy caused by a cardiac troponin T mutation. Clin Transl Sci. 2010; 3(5):219-26. PMC: 2965560. DOI: 10.1111/j.1752-8062.2010.00228.x. View

12.

Kaufman D, Murphy J, Scott J, Hudson K . Subjects matter: a survey of public opinions about a large genetic cohort study. Genet Med. 2008; 10(11):831-9. DOI: 10.1097/GIM.0b013e31818bb3ab. View

13.

Fatkin D, MacRae C, Sasaki T, WOLFF M, Porcu M, Frenneaux M . Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999; 341(23):1715-24. DOI: 10.1056/NEJM199912023412302. View

14.

Murphy J, Scott J, Kaufman D, Geller G, LeRoy L, Hudson K . Public expectations for return of results from large-cohort genetic research. Am J Bioeth. 2008; 8(11):36-43. PMC: 2682364. DOI: 10.1080/15265160802513093. View

15.

Kushner J, Nauman D, Burgess D, Ludwigsen S, Parks S, Pantely G . Clinical characteristics of 304 kindreds evaluated for familial dilated cardiomyopathy. J Card Fail. 2006; 12(6):422-9. DOI: 10.1016/j.cardfail.2006.03.009. View

16.

Miller F, Hayeems R, Bytautas J . What is a meaningful result? Disclosing the results of genomic research in autism to research participants. Eur J Hum Genet. 2010; 18(8):867-71. PMC: 2987386. DOI: 10.1038/ejhg.2010.34. View

17.

Bookman E, Langehorne A, Eckfeldt J, Glass K, Jarvik G, Klag M . Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A. 2006; 140(10):1033-40. PMC: 2556074. DOI: 10.1002/ajmg.a.31195. View

18.

Hershberger R, Hanson E, Jakobs P, Keegan H, Coates K, Bousman S . A novel lamin A/C mutation in a family with dilated cardiomyopathy, prominent conduction system disease, and need for permanent pacemaker implantation. Am Heart J. 2002; 144(6):1081-6. DOI: 10.1067/mhj.2002.126737. View

19.

Meulenkamp T, Gevers S, Bovenberg J, Smets E . Researchers' opinions towards the communication of results of biobank research: a survey study. Eur J Hum Genet. 2011; 20(3):258-62. PMC: 3283180. DOI: 10.1038/ejhg.2011.216. View

20.

Ho C, MacRae C . Defining the pathogenicity of DNA sequence variation. Circ Cardiovasc Genet. 2009; 2(2):95-7. PMC: 3068192. DOI: 10.1161/CIRCGENETICS.109.864793. View